Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients.
The 7-year follow-up with plasma-derived and 2-year follow-up with r-DNA vaccines have indicated the safety, immunogenicity and persistence of a vaccine-induced antibody response in hemodialysis patients. The results of our study indicate that these subjects have a lower and often inadequate immunogenic response to the HB vaccine and that the r-DNA vaccine gives a better seroconversion rate than the plasma-derived vaccines.
Dentico
P
P
Istituto Policattedra Clinica Medica e Malattie Infettive, Università di Bari, Italy.
Volpe
A
A
Buongiorno
R
R
Maracchione
N
N
Carbone
M
M
Manno
C
C
Proscia
F
F
D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines; D006801:Humans; D007115:Immunization Schedule; D006435:Renal Dialysis / Q000009:adverse effects*; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines